SG11201809471UA - Polymorphic forms of 3-[2-butyl-1-(2-diethylamino-ehtyl)-1h-benzoimidazol-5-yl]-n-hydroxy-acrylamide and uses thereof - Google Patents

Polymorphic forms of 3-[2-butyl-1-(2-diethylamino-ehtyl)-1h-benzoimidazol-5-yl]-n-hydroxy-acrylamide and uses thereof

Info

Publication number
SG11201809471UA
SG11201809471UA SG11201809471UA SG11201809471UA SG11201809471UA SG 11201809471U A SG11201809471U A SG 11201809471UA SG 11201809471U A SG11201809471U A SG 11201809471UA SG 11201809471U A SG11201809471U A SG 11201809471UA SG 11201809471U A SG11201809471U A SG 11201809471UA
Authority
SG
Singapore
Prior art keywords
international
benzoimidazol
diethylamino
acrylamide
butyl
Prior art date
Application number
SG11201809471UA
Inventor
David Duncan
Original Assignee
Mei Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mei Pharma Inc filed Critical Mei Pharma Inc
Publication of SG11201809471UA publication Critical patent/SG11201809471UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1111111111 01110101011111 010111110 I 0111110101011111H 01111111011110111111 Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\"\"1 WO 2017/192451 Al 09 November 2017 (09.11.2017) WIP0 I PCT (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/282 (2006.01) A61K 31/4353 (2006.01) kind of national protection available): AE, AG, AL, AM, (21) International Application Number: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, PCT/US2017/030414 CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (22) International Filing Date: HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, 01 May 2017 (01.05.2017) KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (25) Filing Language: English PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (26) Publication Language: English SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (30) Priority Data: TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. 62/330,673 02 May 2016 (02.05.2016) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant: MEI PHARMA, INC. [US/US]; 11975 El GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, Camino Real, Suite 101, San Diego, California 92130 (US). UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (72) Inventor: DUNCAN, David; 9525 Oviedo Street, San TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, Diego, California 92129 (US). EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (74) Agent: GRUMBLING, Matthew V. et al.; WILSON TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, SONSINI GOODRICH & ROSATI, 650 Page Mill Road, KM, ML, MR, NE, SN, TD, TG). Palo Alto, California 94304 (US). = (54) Title: POLYMORPHIC FORMS OF 3-[2-BUTYL-1-(2-DIETHYLAMINO-EHTYL)-1H-BENZOIMIDAZOL-5-YL]-N-HY- DROXY-ACRYLAMIDE AND USES THEREOF = = FIG. 1 = 100 £ = 901 = I = = $ A' 1 = 601 c / = i 1 = _ t 1 :c, gt = _ 46 _ = $01 _ 20 11 11 ,...,•,..ikk..“) Al , . 1 1' t0 i 6 ,:-.4 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 ei 28 r] tT 1-1 IN ,-1 (57) : Crystalline polymorph forms of 342-butyl-1-(2-diethylamino-ethyl)-1H-benzoimidazol-5-y1]-N-hydroxy-acrylamide 0 are described. Pharmaceutical compositions and the uses of such compounds, compound forms, and compositions for the treatment of N diseases and conditions are also presented. [Continued on next page] WO 2017/192451 Al MIDEDIMOMMIDIRMEMOMOHEIDEIVIDEDIIMOVOIMIE Declarations under Rule 4.17: — as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(H)) — as to the applicant's entitlement to claim the earlier application (Rule 4.17(iii)) priority of the Published: — with international search report (Art. 21(3))
SG11201809471UA 2016-05-02 2017-05-01 Polymorphic forms of 3-[2-butyl-1-(2-diethylamino-ehtyl)-1h-benzoimidazol-5-yl]-n-hydroxy-acrylamide and uses thereof SG11201809471UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662330673P 2016-05-02 2016-05-02
PCT/US2017/030414 WO2017192451A1 (en) 2016-05-02 2017-05-01 Polymorphic forms of 3-[2-butyl-1-(2-diethylamino-ehtyl)-1h-benzoimidazol-5-yl]-n-hydroxy-acrylamide and uses thereof

Publications (1)

Publication Number Publication Date
SG11201809471UA true SG11201809471UA (en) 2018-11-29

Family

ID=60203321

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201809471UA SG11201809471UA (en) 2016-05-02 2017-05-01 Polymorphic forms of 3-[2-butyl-1-(2-diethylamino-ehtyl)-1h-benzoimidazol-5-yl]-n-hydroxy-acrylamide and uses thereof

Country Status (20)

Country Link
US (2) US10626092B2 (en)
EP (2) EP3939966A1 (en)
JP (1) JP2019514905A (en)
KR (1) KR20190005904A (en)
CN (1) CN109414425A (en)
AR (1) AR108257A1 (en)
AU (1) AU2017261218A1 (en)
BR (1) BR112018072439A2 (en)
CA (1) CA3022011A1 (en)
CL (1) CL2018003109A1 (en)
CO (1) CO2018012941A2 (en)
EA (1) EA201892341A1 (en)
ES (1) ES2886495T3 (en)
IL (1) IL262578A (en)
MA (1) MA44880A (en)
MX (1) MX2018013349A (en)
PH (1) PH12018502296A1 (en)
SG (1) SG11201809471UA (en)
TW (1) TW201741286A (en)
WO (1) WO2017192451A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018157742A1 (en) * 2017-02-28 2018-09-07 苏州科睿思制药有限公司 Crystalline form of salt of sb-939, preparation method therefor, and use
WO2019126282A1 (en) 2017-12-19 2019-06-27 Assia Chemical Industries Ltd. Crystalline polymorphs of pracinostat and pracinostat salts
WO2019149262A1 (en) * 2018-02-05 2019-08-08 苏州科睿思制药有限公司 Crystal form of sb-939, preparation method and use thereof
WO2021217180A1 (en) 2020-04-22 2021-10-28 Johnson Matthey Public Limited Company Novel forms of pracinostat dihydrochloride

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2291749A1 (en) 1974-11-20 1976-06-18 Delalande Sa 5-carboxyalkyl-benzimidazole derivs - with analgesic, sedative, hypertensive or hypotensive, bronchodilatory, anticholinergic and vasodilatory activity
ATE198601T1 (en) 1992-05-20 2001-01-15 Merck & Co Inc ESTER DERIVATIVES OF 4-AZA STEROIDS
SE9804212D0 (en) 1998-12-04 1998-12-04 Astra Pharma Prod Compounds
ATE302193T1 (en) 1999-01-13 2005-09-15 Warner Lambert Co BENZOHETEROCYCLES AND THEIR USE AS MEK INHIBITORS
US6498165B1 (en) 1999-06-30 2002-12-24 Merck & Co., Inc. Src kinase inhibitor compounds
AU6605200A (en) 1999-06-30 2001-01-31 Merck & Co., Inc. Src kinase inhibitor compounds
ATE250932T1 (en) 1999-07-16 2003-10-15 Warner Lambert Co METHOD FOR TREATING CHRONIC PAIN BY ADMINISTRATION OF A MEK INHIBITOR
HUP0202319A3 (en) 1999-07-16 2004-12-28 Warner Lambert Co Use of mek inhibitors for the preparation of pharmaceutical compositions treating chronic pain
GB9919558D0 (en) 1999-08-18 1999-10-20 Hoechst Schering Agrevo Gmbh Fungicidal compounds
DK1233958T3 (en) 1999-11-23 2011-10-17 Methylgene Inc Inhibitors of histone deacetylase
ID30204A (en) 1999-12-27 2001-11-15 Japan Tobacco Inc COMPOUNDS OF DIFFUSED RING AND ITS USE AS A MEDICINE
US6770666B2 (en) 1999-12-27 2004-08-03 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
PE20020354A1 (en) 2000-09-01 2002-06-12 Novartis Ag HYDROXAMATE COMPOUNDS AS HISTONE-DESACETILASE (HDA) INHIBITORS
CA2428191A1 (en) 2000-11-07 2002-05-30 Bristol-Myers Squibb Company Acid derivatives useful as serine protease inhibitors
PA8535601A1 (en) 2000-12-21 2002-11-28 Pfizer BENZIMIDAZOL AND PIRIDILIMIDAZOL DERIVATIVES AS LIGANDOS FOR GABAA
CA2450555A1 (en) 2001-06-25 2003-01-03 Merck & Co., Inc. (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds
AR035543A1 (en) 2001-06-26 2004-06-16 Japan Tobacco Inc THERAPEUTIC AGENT FOR HEPATITIS C THAT INCLUDES A CONDENSED RING COMPOUND, CONDENSED RING COMPOUND, PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS, BENZIMIDAZOL, THIAZOL AND BIFENYL COMPOUNDS USED AS INTERMEDIARY COMPARTMENTS OF COMPARTMENTS
JP2005517007A (en) 2002-02-07 2005-06-09 アクシス・ファーマスーティカルズ Novel bicyclic hydroxamates as histone deacetylase inhibitors
UA76837C2 (en) 2002-03-13 2006-09-15 Еррей Байофарма Інк. N3 alkylated derivatives of benzimidazole as mek inhibitors
SG148857A1 (en) 2002-03-13 2009-01-29 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
CN1659161A (en) 2002-04-16 2005-08-24 帝人株式会社 Piperidine derivatives having CCR3 antagonism
DE10239042A1 (en) 2002-08-21 2004-03-04 Schering Ag New fused macrocyclic pyrimidine derivatives, useful as e.g. cyclin-dependent kinase inhibitors for treating e.g. cancer, autoimmune, cardiovascular or neurodegenerative diseases or viral infections
US7151096B2 (en) 2003-03-05 2006-12-19 Irm Llc Cyclic compounds and compositions as protein kinase inhibitors
JP2006520796A (en) 2003-03-17 2006-09-14 タケダ サン ディエゴ インコーポレイテッド Histone deacetylase inhibitor
JP5042626B2 (en) 2003-09-22 2012-10-03 エス＊バイオ プライベート リミティッド Benzimidazole derivatives: production and pharmaceutical applications
WO2005065681A1 (en) 2003-12-19 2005-07-21 Takeda San Diego, Inc. N- hydroxy-3-(3-(1h-imidazol-2-yl)-phenyl)-acrylamide derivatives and related compounds as histone deacetylase (hdac) inhibitors for the treatment of cancer
US20050137234A1 (en) 2003-12-19 2005-06-23 Syrrx, Inc. Histone deacetylase inhibitors
WO2006101456A1 (en) 2005-03-21 2006-09-28 S*Bio Pte Ltd Bicyclic heterocycles hydroxamate compounds useful as histone deacetylase (hdac) inhibitors
WO2007030080A1 (en) 2005-09-08 2007-03-15 S*Bio Pte Ltd Heterocyclic compounds
AU2006201177B2 (en) * 2005-09-08 2012-06-14 Mei Pharma, Inc. Heterocyclic compounds
EP2131840B1 (en) 2007-03-07 2018-10-17 MEI Pharma, Inc. Combination of benzimidazole anti-cancer agent and a second anti-cancer agent
EP2914254B1 (en) 2012-10-30 2020-01-08 MEI Pharma, Inc. Combination therapies to treat chemoresistant cancers

Also Published As

Publication number Publication date
MA44880A (en) 2021-03-17
EP3939966A1 (en) 2022-01-19
BR112018072439A2 (en) 2019-02-19
PH12018502296B1 (en) 2019-07-08
WO2017192451A1 (en) 2017-11-09
PH12018502296A1 (en) 2019-07-08
JP2019514905A (en) 2019-06-06
US10626092B2 (en) 2020-04-21
CO2018012941A2 (en) 2018-12-28
AU2017261218A1 (en) 2018-11-29
KR20190005904A (en) 2019-01-16
AR108257A1 (en) 2018-08-01
US20200317621A1 (en) 2020-10-08
EP3452035A4 (en) 2019-09-25
IL262578A (en) 2018-12-31
MX2018013349A (en) 2019-02-20
EA201892341A1 (en) 2019-05-31
ES2886495T3 (en) 2021-12-20
US20190152923A1 (en) 2019-05-23
CL2018003109A1 (en) 2019-04-26
CA3022011A1 (en) 2017-11-09
TW201741286A (en) 2017-12-01
CN109414425A (en) 2019-03-01
EP3452035A1 (en) 2019-03-13
EP3452035B1 (en) 2021-07-07

Similar Documents

Publication Publication Date Title
SG11201908330PA (en) Farnesoid x receptor agonists and uses thereof
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201900745VA (en) Substituted thiazolo-pyridine compounds as malt1 inhibitors
SG11201903182XA (en) 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer
SG11201803920TA (en) Compounds and compositions useful for treating disorders related to ntrk
SG11201407220YA (en) N-alkyltriazole compounds as lpar antagonists
SG11201907840RA (en) Fused imidazo-piperidine jak inhibitors
SG11201809751XA (en) Egfr inhibitor compounds
SG11201807784SA (en) 3-desoxy derivative and pharmaceutical compositions thereof
SG11201900349VA (en) Somatostatin modulators and uses thereof
SG11201407228PA (en) N-aryltriazole compounds as lpar antagonists
SG11201909155VA (en) Ask1 inhibitor compounds and uses thereof
SG11201803627XA (en) N-substituted indole derivatives as pge2 receptor modulators
SG11201811230RA (en) Compositions and methods for reducing ocular neovascularization
SG11201908512YA (en) Somatostatin modulators and uses thereof
SG11201909680UA (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
SG11201809471UA (en) Polymorphic forms of 3-[2-butyl-1-(2-diethylamino-ehtyl)-1h-benzoimidazol-5-yl]-n-hydroxy-acrylamide and uses thereof
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201909807TA (en) Methods of manufacturing of niraparib
SG11201903055UA (en) Inhibitors of glucocorticoid receptor
SG11201805170XA (en) Cellular glycosaminoglycan compositions and methods of making and using
SG11201900633XA (en) Piperidine cxcr7 receptor modulators
SG11201809162XA (en) 6-aminopyridin-3-yl thiazoles as modulators of ror?t
SG11201901999XA (en) Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making